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Heart disease is one of the lead causes of death worldwide. Many forms of heart disease, including myocardial infarction and
pressure-loading cardiomyopathies, result in irreversible cardiomyocyte death. Activated fibroblasts respond to cardiac injury
by forming scar tissue, but ultimately this response fails to restore cardiac function. Unfortunately, the human heart has little
regenerative ability and long-term outcomes following acute coronary events often include chronic and end-stage heart failure.
Building upon years of research aimed at restoring functional cardiomyocytes, recent advances have been made in the direct
reprogramming of fibroblasts toward a cardiomyocyte cell fate both in vitro and in vivo. Several experiments show functional
improvements in mouse models of myocardial infarction following in situ generation of cardiomyocyte-like cells from endogenous
fibroblasts. Though many of these studies are in an early stage, this nascent technology holds promise for future applications in
regenerative medicine. In this review, we discuss the history, progress, methods, challenges, and future directions of direct cardiac
reprogramming.
1. Introduction
Cardiac diseases cause major morbidity andmortality world-
wide. The American Heart Association’s yearly review of car-
diovascular disease reports that 1 out of every 7 deaths in the
United States in 2011 was caused by coronary heart disease [1].
Coronary heart disease predisposes to acute cardiac injuries
such as myocardial infarction (MI), which often result in sig-
nificant and permanent losses of functional cardiomyocytes.
Because the human heart has minimal ability for endoge-
nous cardiomyocyte regeneration [2], reparative responses
to cardiac cell death primarily rely on activated fibroblasts
forming scar tissue.This response to injury fails to restore car-
diomyocyte function and often leads to undesirable outcomes
including development of arrhythmias and chronic heart
failure. Unfortunately, short of heart transplantation, current
therapies do not restore declining pump function following
cardiac injury. Efforts to address this issue have led to the
exploration of several cellular approaches aimed at restoring
functional cardiomyocytes; these include stimulating expan-
sion and differentiation of endogenous cardiac progenitor
cells and lineage differentiation of embryonic stem cells
or induced pluripotent stem cells. An alternative approach
centers on converting nonmyocyte cells directly into new car-
diomyocytes (Figure 1). Recently, promising advances have
been achieved by directly reprogramming mouse cardiac
fibroblasts (CFs) into functional cardiomyocytes in vitro and
in vivo by transcription factor expression [3, 4]. Specific
combinations of microRNA (miRs) have also been reported
to yield similar reprogramming [5]. In human cells, direct
reprogramming has also been used to convert dermal and
cardiac fibroblasts to cardiomyocytes by specific transcrip-
tion factor combinations or combinations of transcription
factors and miRs [6–8]. Together, these studies describe
exciting developments in direct cardiac reprogramming and
highlight the potential that cellular therapies hold for future
regenerative cardiac therapies. Here, we review the history,
recent advances, major challenges, and future directions of
direct cardiac reprogramming.
2. Master Genes Regulate Cell Fate
In 1986, theWeintraub laboratory [9] laid the groundwork for
muscle cell reprogramming by demonstrating that somatic
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Figure 1: Methods of direct cardiac reprogramming. Several approaches for converting mouse or rat fibroblasts to cardiomyocyte-like cells
in vitro and in vivo have been reported and are summarized here. In vitro reprogramming predominantly yields partially reprogrammed cells,
while in vivo reprogramming yields more mature, fully reprogrammed cardiomyocyte-like cells. iCMs denotes induced cardiomyocytes.
cells could be induced to adopt a skeletal muscle cell fate in
vitro, through overexpression of the skeletal muscle master
regulator gene,MyoD. Their experiments showed that forced
expression of theMyoD gene, which encodes a transcription
factor containing a basic helix-loop-helix (bHLH) domain,
was capable of inducing expression of several muscle-specific
proteins includingmyosin heavy chain andmuscle creatinine
kinase [10]. The ability of master regulator genes to govern
cell fate changes in vivo was later shown by Halder et al.
[11] who ectopically expressed eyeless, the fly homologue
of the vertebrate Pax6 gene, in Drosophila and observed
ectopic formation of eye structures. Similarly, Santerre et al.
[12] showed that transgenic mice overexpressing bmyf, the
bovine homolog of the human bHLH domain-containing,
myogenic determination transcription factor gene myf5,
developed skeletal-muscle like cells in the brain. Together,
these studies led to the recognition that in vivo ectopic
expression of specific master regulator genes could stimulate
cell fate changes. Indeed, in vivo reprogramming was also
achieved by Murry et al. [13] who reported that adenovirus
delivery of MyoD to cryoinjured myocardium in rats could
cause cardiac fibroblast conversion to skeletal muscle cells.
However, successful myogenic conversion, determined by
coexpression ofMyoD and sarcomere myosin, required high
viral doses and occurred in only 14% of MyoD-expressing
cells.The lower efficiency of conversion suggests the existence
of substantial barriers to the described method of skele-
tal muscle reprogramming. Nevertheless, these discoveries
formed the foundation of direct cellular reprogramming by
transcription factor expression and served as an impetus
for current advancements in the generation of induced
cardiomyocytes.
3. Induced Pluripotency and
Direct Cellular Reprogramming
In the 1960s, Gurdon [14] challenged the view of permanently
fixed cell fates by showing that transfer of a somatic cell
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nucleus into an enucleated frog egg could reprogram the
somatic nucleus to a pluripotent state. In 2006, Takahashi and
Yamanaka [15] discovered that conversion of somatic cells to
pluripotency could be achieved by coexpressing four tran-
scription factors. They successfully reprogrammed mouse
fibroblasts to induced pluripotent stem cells (iPSCs) using
transcription factors Oct4, Sox2, Klf4, and c-Myc (OSKM).
The possibility of changing somatic cells to potentially any
other cell lineages sparked many exciting developments in
iPSC technology, which are summarized in several other
reviews [16, 17]. Advances in iPSC technology also encour-
aged novel directions in direct cellular reprogramming.
Breaking from theMyoDmodel of single transcription factor-
mediated reprogramming, laboratories worldwide began
reporting combinations of transcription factors that could
induce different cell fate changes. Efe et al. [18] reported that
addition of a small molecule Janus kinase (JAK) inhibitor in
mouse embryonic fibroblasts (MEFs) transiently expressing
OSKM factors in reprogramming media modified to hin-
der iPSC induction and promote cardiomyogenesis resulted
in formation of spontaneously contracting cardiomyocyte
colonies. While there was a minute (1%) population of
iPSC-like cells achieved following this method, the authors
determined that iPSC and cardiomyocyte generation were
parallel processes; that is, reprogramming to cardiac cell
fate was unlikely to have passed through a pluripotent
intermediate [18]. This study was the first to show car-
diomyocyte generation from MEFs by the combination of
transcription factor expression, specific culture conditions,
and small molecules. The breadth of direct reprogramming
applications for generating a variety of cell lineages has also
been demonstrated by many other laboratories. Utilizing a
specific combination of three transcription factors, Zhou et
al. [19] directly reprogrammed exocrine pancreas cells into
insulin-secreting pancreatic𝛽-cells in vivo. Shortly thereafter,
direct reprogramming of fibroblasts into other cell lineages
generated neurons [20], hepatocytes [21], endothelial cells
[22], hematopoietic stem cells [23], and cardiomyocytes [4].
Herein, we will discuss advances specifically related to direct
cardiac reprogramming.
4. In Vitro Direct Cardiac Reprogramming
With the success of reprogramming to pluripotency achieved
through expression of a combination of transcription factors,
efforts to identify a master regulator for cardiomyocyte
transdifferentiation shifted toward efforts to identify multiple
factors that together could activate the cardiac program. In
2010, Ieda et al. [4] identified a combination of three tran-
scription factors, Gata4, Mef2c, and Tbx5 (GMT), that was
sufficient to convert mouse cardiac and dermal fibroblasts
into functional cardiomyocyte-like cells in vitro. In order to
identify theGMTreprogramming factors, the authors created
an in vitro assay to determine the minimal number of factors
required to convert nonmyocyte cells into a cardiomyocyte
cell fate. Transgenicmice were generated to express enhanced
green fluorescent protein (EGFP) driven by the 𝛼-myosin
heavy chain (𝛼MHC) promoter, which is activated in mature
cardiomyocytes and thus permits their identification by
green fluorescence. Cardiac fibroblasts were extracted from
neonatal transgenic mice and 𝛼MHC-EGFP−/Thy1+ fibrob-
lasts were purified by fluorescence-activated cell sorting
(FACS). Fourteen transcription factors of known importance
in cardiac development were then retrovirally overexpressed
in the purified cardiac fibroblasts. A small number of EGFP-
positive cells were observed, suggesting successful cell fate
conversion. Serial deletion of individual transcription factors
from the original pool of 14 transcription factors yielded
the three transcription factors, GMT, which together were
capable of inducing EGFP expression in 15–20% of cells,
termed induced cardiomyocytes (iCMs). While some iCMs
expressed additional cardiac markers like cardiac Troponin T
(cTnT) and sarcomeric𝛼-actinin, assembled sarcomere struc-
tures, and demonstrated global enrichment in transcripts
similar to the cardiomyocyte transcriptome, the majority of
iCMs were likely only partially reprogrammed.
Despite this, many iCMs could generate Ca2+ transients
and 4 weeks after reprogramming, spontaneous beating was
observed in ≈0.5% of 𝛼MHC-EGFP+/cTnT+ iCMs, which
also exhibited action potentials comparable to those of adult
ventricular cardiomyocytes [4]. Furthermore, iCMs demon-
strated epigenetic shifts toward a neonatal cardiomyocyte-
like state at the cardiac-specific genes Actn2, Ryr2, and
TnnT2, suggesting that reprogrammingwith theGMT factors
induces changes in the epigenetic status of reprogramming
cells.While it is possible that the observed iCMswere actually
remote cardiac progenitor cells contaminating the fibroblast
population, this is unlikely for two reasons. First, use of
genetic lineage tracing showed that iCMs did not express
cardiac progenitor markers (i.e., Mesp1 and Isl1) during
reprogramming. Second, the GMT factors also successfully
reprogrammed 15% of neonatal tail-tip fibroblasts (TTF)
to 𝛼MHC-EGFP+ iCMs, which also showed expression of
cTnT and generation of Ca2+ transients; these TTF-derived
iCMs, however, did not beat and the efficiency of their
generation was reduced. While these results demonstrate
exciting developments in direct cardiac reprogramming, the
efficiency of in vitro direct reprogramming by this method is
low (<1%) but comparable to the efficiency of iPSC generation
[4, 15]. Shortly after this study, Song et al. [24] discovered
that addition of Hand2, a bHLH transcription factor, to the
GMT cocktail of factors (together termed GHMT) could
induce adult TTFs into beating iCMs. In identifying Hand2,
Song et al. [24] isolated cardiac fibroblasts from 𝛼MHC-GFP
transgenic mice and retrovirally expressed six core transcrip-
tion factors involved in cardiac development: Hand2, Mesp1,
Nkx2.5, and the GMT factors. Serial deletion of transcription
factors revealed several factor combinations that efficiently
induced GFP expression. In examining these factors for
their ability to induce cTnT expression in adult TTFs,
the GHMT cocktail was identified as producing a 4-fold
increased conversion of adult TTFs to 𝛼MHC-EGFP+/cTnT+
iCMs compared to GMT reprogramming of neonatal TTFs.
These TTF-derived iCMs formed sarcomeres, generated Ca2+
transients, and showed a cardiomyocyte-like transcriptome
profile. Additionally, 5 weeks after GHMT reprogramming of
TTFs, a small population of these iCMswere observed to beat
4 BioMed Research International
spontaneously, demonstrating that GHMT could directly
reprogramTTFs to functional iCMs. In a different study with
the GHMT factors, Hirai et al. [25] fused the GHMT factors
to the MyoD activation domain and observed accelerated
reprogramming and increased numbers of beating iCMs.
More recently, Nam et al. [26] demonstrated that in vitro
GHMT reprogramming of fibroblasts into cardiomyocytes
resulted in a range of phenotypes, including immature
forms of atrial, ventricular, and pacemaker cells. Using
multiplex immunostaining and patch clamping, the authors
first identified unique constellations of cardiac markers and
electrical activity that reliably defined atrial, ventricular, and
pacemaker cardiomyocyte subtypes in Hcn4-GFP reporter
mice, where GFP expression is driven by the promoter of
Hcn4, a pacemaker-specific potassium channel gene. On a
single cell level, they determined thatGHMTreprogramming
of MEFs derived from Hcn4-GFP reporter mice resulted in
iCMs with immature phenotypes of all three major forms
of cardiac cells, thus demonstrating an exceptional degree of
plasticity intrinsic to GHMT reprogramming and providing
a starting point for deciphering cardiac cell subtype-specific
reprogramming.
The previously described methods by Ieda et al. [4] and
Song et al. [24] for identifying reprogramming factors relies
on 𝛼MHC-EGFP reporter activation. Although this may
hone in on crucial reprogramming factors, this strategy may
also suffer from biased identification of factors that efficiently
activate the 𝛼MHCpromoter, while excluding those that may
promote full reprogramming. To address this issue, Protze
et al. [27] screened 120 different triplet combinations of 10
candidate reprogramming factors for their ability to activate
expression of five cardiac genes (Myh5, Myl2, Actc1, Nkx2.5,
and Scn5a) in mouse fibroblasts. Expression of Tbx5, Mef2c,
and Myocd together upregulated the most cardiac genes
examined. Although fibroblasts transduced with these three
factors indeed expressed cardiac cell fate indicators, such
as contractile proteins, cardiac-like sodium and potassium
currents, and inducible action potentials, these iCMs failed
to spontaneously beat. Other groups developed alternative
criteria for reprogramming factor combination screening.
Christoforou et al. [28] assayed different combinations of 10
transcription factors for their ability to induce cardiomyocyte
conversion in MEFs. Criteria for identifying factor com-
binations included activation of cardiac-specific promoters
and specific cardiac genes, cardiac morphologic features, and
functional capacities including resting membrane potential
and spontaneous beating. Through this method, the authors
determined that Myocd and SRF could improve GMT repro-
gramming; however, no spontaneous contractile activity was
observed.
In another recent study, Addis et al. [29] sought to
optimize direct cardiac conversion by using a quantifiable
calcium-reporter, GCaMP driven by the cTnT promoter,
to screen candidate factor combinations for the ability to
induce functional transdifferentiation in MEFs. Using this
method Hand2, Nkx2.5, Gata4, Mef2c, and Tbx5 (HNGMT)
were identified as the optimal combination for inducing
robust calcium oscillation and an increase in spontaneously
beating iCMs compared to GMT reprogramming alone.
In a subsequent study utilizing the same calcium reporter,
Ifkovits et al. [30] showed that the small molecule TGF-
𝛽 Inhibitor SB432542 increased the efficiency of HNGMT
reprogramming 5-fold.
While most of these studies focused on transcription-
factor mediated reprogramming, Jayawardena et al. [5]
reported successful conversion of neonatal mouse fibroblasts
to cardiomyocyte-like cells in vitro through the combination
of 4 miRs: miR-1, -133, -208, and -499. Addition of a
JAK inhibitor (JI1) resulted in enhanced reprogramming
efficiency as well as spontaneously beating iCMs. Extending
the capabilities of the miR reprogramming, Muraoka et al.
[31] showed that addition of miR-133a to the combination
of GMT in MEFs yielded a 7-fold increase in beating iCMs
compared with GMT reprogramming alone; miR-133a was
shown to repress Snai1, a master regulator of epithelial-to-
mesenchymal transitions, suggesting that suppressing fibrob-
last signatures may be critical in reprogramming fibroblasts
to iCMs. Taken together, these studies demonstrate that
many approaches and criteria are used to screen for cardiac
reprogramming factors and to validate cardiac cell fate
conversion. For instance, some studies evaluate expression
of cardiac specific genes by targeted qPCR, which is not as
comprehensive an evaluation as global transcriptome profil-
ing. Regardless, the numerous recent developments in direct
cardiac reprogramming in vitro (Figure 1) are promising for
significant advances in current methods and understanding
of this emerging technology.
5. In Vivo Direct Cardiac Reprogramming
Building upon decades of cardiovascular biology research,
which elucidated transcriptional factor networks important
in embryonic heart development, in 2009 Takeuchi and
Bruneau [32] discovered that overexpression of transcription
factors of Gata4, Tbx5, and chromatin remodeling protein,
Baf60c, in noncardiogenicmesodermwas sufficient to induce
spontaneously contracting cardiomyocytes in 50% of trans-
fected mouse embryos. In the absence of Tbx5 from this
combination of reprogramming factors, differentiation into
the cardiac lineage was still promoted; however, resultant car-
diomyocytes did not spontaneously contract.The demonstra-
tion that robust beating iCMs could be induced in vivo with
coexpression of Gata4, Tbx5, and Baf60, which together were
not identified as promoting in vitro cardiac reprogramming
[4, 32] suggests that elements of the nativemicroenvironment
may be conducive to the reprogramming process. Direct
cardiac reprogramming in vivomight, therefore, be expected
to yield significantly higher conversion efficiencies than in
vitro.
To test this hypothesis, Qian et al. [3] retrovirally deliv-
ered GMT to peri-infarct areas in 2-month-old male mice
after coronary artery ligation and observed an increased
efficiency of iCM conversion compared to in vitro GMT
reprogramming. Cre-based lineage tracing studies were used
to determine the origin of retrovirally infected iCMs. In the
reprogrammed infarct area, a portion of cells with sarcomere
structures and cardiomyocyte morphology were positive for
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both fibroblast and cardiomyocyte lineage markers (Fsp1-
Cre and Periostin-Cre). Importantly, lineage tracing using
𝛼MHC-MerCreMer mice was used to rule out the possibility
that cell-cell fusion was responsible for observed iCMs.
These in vivo iCMs shared many features with endogenous
cardiomyocytes.Theywere binucleate, with clearly assembled
sarcomeres, and they demonstrated cardiac-specific gene
expression. Furthermore, single-cell analysis of iCM electro-
physiology revealed that half of iCMs exhibited ventricular
cardiomyocyte-like action potentials upon electric stimula-
tion. Remarkably, iCMs electrically coupled with endoge-
nous iCMs, which is crucial for potential future clinical
applications. Importantly, GMT delivery in vivo to infarcted
mouse myocardium also showed decreased scar formation
and improved cardiac functioning, as assessed by MRI and
echocardiography.
Along with this study on in vivo cardiac reprogramming,
other independent laboratories have reported modifications
to GMT factor reprogramming methods. Song et al. [24]
found that addition of Hand2 to the GMT factors could effi-
ciently induce expression of cardiacmarkers in vivo. Also, the
resultant iCMs were similar to endogenous cardiomyocytes
in morphology, with rod shaped structures and assembled
sarcomeres, as well as in functionality, with many iCMs
generating Ca2+ transients and action potentials. As with
GMT factor reprogramming, theGHMT factorswere capable
of decreasing scar size and improving pump functioning in
infarcted mouse hearts.
In another example of in vivo GMT factor reprogram-
ming, Inagawa et al. [33] demonstrated similar findings
to Qian et al. [3]. However, the novelty of this study
involved alternative experimental methods aimed at improv-
ing reprogramming efficiency. In contrast to the multiple
retroviral deliveries of GMT factors used by Qian et al.
[3], Inagawa et al. [33] used a single promoter polycistronic
retrovirus containing GMT with intervening sequences of
2A self-cleaving peptides, which permitted more homoge-
nous GMT expression. Additionally, immunosuppression of
mice treated with retrovirus aided in preventing immune-
mediated destruction of transduced cells. Although this
study lacked functional characterization of iCMs, the novel
experimental modifications significantly improved in vivo
iCM generation. Building on the goal of more homogenous
gene expression of reprogramming factors, Mathison et al.
[34] also generated a single-promoter polycistronic vector
encoding GMT and 2A self-cleaving peptides. Compared to
multiple viral delivery of GMT, polycistronic GMT delivery
to infarcted rat hearts resulted in a 2-fold increase in iCM
generation as well as enhanced ventricular function.
Adding another twist to transcription-factor-mediated
cardiac reprogramming, several other groups began inves-
tigating the impact of small molecule addition to the GMT
cocktail of factors. Mathison et al. [35] added expression of
three major VEGF isoforms to GMT factor expression in
infarcted rat hearts. Compared to treatment withGMT alone,
treatment withGMT factors andVEGF in infarcted rat hearts
resulted in decreased fibrosis and a 4-fold increase in ejection
fraction. Supporting the role of additional compounds in
enhancing GMT factor reprogramming, Srivastava et al.
[36] demonstrated that addition of a fibroblast activator,
thymosin 𝛽4, to the GMT reprogramming cocktail also
increased the number of reprogrammed iCMs. Alternative
methods to transcription factor reprogramming have also
been demonstrated. Jayawardena et al. [5] reprogrammed
mouse fibroblasts to cardiomyocyte-like cells in vivo using
the combination of miR-1, -133, -208, and -499. Later,
it was shown that JAK inhibitor with miR-1 was alone
sufficient to reprogram fibroblasts into cardiomyocyte-like
cells. More recently, Jayawardena et al. [37] showed that
delivery of this miR combination to peri-infarct regions of
mouse myocardium resulted in cardiomyocyte-like cells with
mature features including sarcomere structure, excitation-
contraction coupling, and action potentials similar to those
of mature ventricular cardiomyocytes. Serial echocardiog-
raphy also revealed progressive improvements in left ven-
tricular functioning starting 1 to 2 months postsurgery
and enhanced functioning at 3-month follow-up. Together
these novel approaches to in vivo cardiac reprogramming
show significantly greater reprogramming efficiencies than
in vitro experiments and demonstrate the crucial role of
the microenvironment in nurturing iCM generation. Local
paracrine agents, tensile forces, extracellular matrix, and
other unknown factors likely facilitate maturation of iCMs,
and surely this will be an active area of exciting new
developments to come.
6. Direct Reprogramming of Human
Fibroblasts to a Cardiac Cell Fate
Considering the abundant supply of cardiac fibroblasts
(>50%) in the human heart [38], a clinically important step
for the direct cardiac reprogramming field will be to translate
reprogramming technology to human fibroblasts. Nam et
al. [6] reported successful induction of cTnT expression in
human fibroblasts by use of transcription factors Gata4,
Hand2, Tbx5, and Myocd together with miR-1 and -133.
Although iCMs showed sarcomere assembly, expression of
some cardiac genes, downregulation of fibroblast genes, and
Ca2+ transients, the vastmajority of iCMs failed to upregulate
a host of cardiac genes and spontaneously beating iCMs
were sparse, suggesting a partially reprogrammed state in the
majority of transduced cells. Using only transcription factors,
Fu et al. [7] aimed to demonstrate in vitro reprogramming
of human fibroblasts to iCMs with the GMT factors. GMT
alone did not result in reprogramming of human fibroblasts;
however, addition of MESP1 and ESRRG to the GMT factor
mix resulted in global shifts in cardiac gene-expression
and changes in phenotype toward cardiac morphology [7].
Adding Myocd and ZFPM2 to this cocktail further improved
reprogramming, with resultant iCMs assembling sarcomeres
and exhibiting cardiac cell-like electrophysiology [7]. How-
ever, the iCMs were not observed to beat, even long after
reprogramming, despite demonstrating similar global gene
expression levels as were achieved by GMT reprogramming
of mouse fibroblasts in vitro [7]. Wada et al. [8] also
demonstrated that GMT factors, MESP1 andMyocd together
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were capable of inducing cardiac gene expression in human
fibroblasts, although the iCMs did not beat spontaneously.
Interestingly, culturing these iCMs with mouse cardiomy-
ocytes resulted in their beating [8]. While these studies
demonstrate that human fibroblasts are indeed amenable to
cardiac reprogramming, they also underscore the need to
better understand the barriers to complete reprogramming as
well as the mechanism of reprogramming. Recently, several
groups have made exciting headway in these directions.
7. Challenges and Future Objectives
While many exciting developments have been made in
the emerging field of direct cardiac reprogramming, many
challenges must be addressed to move this technology closer
toward applications in disease modeling, drug screening
and ultimately toward treating human heart diseases. One
challenge is the current inefficiency of in vitro cardiac
reprogramming in both human and mouse fibroblasts. The
first reported method of in vitro reprogramming fibroblasts
into iCMs by GMT cocktail demonstrated an efficiency of
iCM generation at <1%, though the efficiency was remarkably
higher in vivo [3, 4]. Later, the use of a single-promoter,
polycistronic vector encoding the GMT factors increased
the number of iCMs generated in vivo compared to use of
separate virus delivery of GMT [33, 34]. Most recently, Wang
et al. [39] demonstrated that an important determinant in
both the efficiency and the quality of iCMgeneration relies on
stoichiometric expression of the GMT factors [39]. By testing
the reprogramming efficiencies of 6 polycistronic constructs
encompassing all possible combinations of the GMT factors,
Wang et al. [39] determined that high expression of Mef2c,
which was observed with the polycistronic MGT construct,
resulted in a 10-fold increase in the number of beating
iCMs compared to separate viral transduction of the GMT
factors. Together these results point to homogenous and
stoichiometric expression of reprogramming factors as key
elements of successful reprogramming. While many stud-
ies have achieved successful reprogramming, other groups
have had less success [40], which further emphasizes the
requirement for optimization of experimental conditions.
Nevertheless, continued progress in increasing the efficiency
of in vitro reprogrammingwill be necessary to facilitate future
studies into the mechanism of reprogramming.
Importantly, it is also necessary to understand how epi-
genetic barriers are overcome and how new epigenetic states
are established and maintained during reprogramming into
functionally mature iCMs. Epigenetic barriers may in part
account for cell-to-cell differences in amenability to complete
reprogramming and thus explain why some populations of
iCMs remain partially reprogrammed or appear refractory to
complete reprogramming, while others are reprogrammed to
functionally mature states. Given the increased efficiency of
in vivo reprogramming [3], it is likely that small molecules,
paracrine factors, and other unknown factors and mech-
anisms inherent to the native cardiac environment play
a role in the functional maturation of iCMs. Identifying
these maturation-promoting factors as well as elucidating the
epigenetic and transcriptional changes in cells undergoing
reprogramming will be important for the development of
iCMs for in vitro applications, such as drug toxicity screening
and disease modeling, or in vivo applications, such as in situ
generation of iCMs following myocardial infarction.
Given the high demand for regenerative therapies to
treat injuries in essential, poorly regenerative organs, such
as the heart, a direct cellular reprogramming approach may
be especially well suited for treatment of cardiac disease.
Currently, regenerative cardiac therapies undergoing clinical
trials involve explant culture of autologous cardiac-derived
cells (CDCs) and transplant in patients with chronic heart
failure or several months after MI [41]. Transplant-based
CDC therapies, such as autologous human cardiac-derived
stem cells, have shown some functional benefit and reduced
infarct scar size; however, evidence shows lack of signifi-
cant long-term cell engraftment, though tissue-engineering
approaches may improve engraftment. Also, the requirement
for several months of explant culture to generate cardiomy-
ocytes for individual patients hinders future scaling-up of
this treatment as well as utilization in acute MI settings.
Given that direct cardiac reprogramming can generate iCMs
in situ in peri-infarct regions following acute coronary events
in animal models, this nascent technology could potentially
address issues faced by other cardiac regenerative approaches.
Direct cardiac reprogramming is, therefore, an area of study
that merits continued investigation. Despite the many chal-
lenges in this emerging field of study, significant progress is
being made to advance this technology toward regenerative
medicine applications in the near future.
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